Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy

Acta Dermato-Venereologica

Volumn 88, Issue 6, 2008, Pages 547-554

  de Hass, Ellen R M ^a   de Bruijn, Henriette S ^a   Sterenborg, Henricus J C M ^a   Neumann, H A Martino ^a   Robinson, Dominic J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ALA PDT; Basal cell carcinoma; Fluorescence kinetics; Ki57; PpIX

Indexed keywords

AMINOLEVULINIC ACID; KI 67 ANTIGEN; PROTOPORPHYRIN;

ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; ILLUMINATION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIGHT DARK CYCLE; LIGHT INTENSITY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUMOR BIOPSY;

AMINOLEVULINIC ACID; BIOPSY; CARCINOMA, BASAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICROSCOPY, FLUORESCENCE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SKIN; SKIN NEOPLASMS;

EID: 56749109910     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0508     Document Type: Article

References (36)

1. de Haas ERM, Kruijt B, Sterenborg HJCM, Neumann HAM, Robinson DJ. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic-acid photodynamic therapy. J Invest Dermatol 2006; 126: 2679-2686.
2. Star W, van't Veen AJ, Robinson DJ, Munte K, de Haas ERM, Sterenborg HJCM. 5-aminolaevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two hour interval. Acta Derm Venereol 2006; 86: 412-417.
3. van der Veen N, van Leengoed HLLM, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. Br J Cancer 1994; 70: 867-872.
4. van der Veen N, Hebeda KM, de Bruijn HS, Star WM. Photodynamic effectiveness and vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single or two-fold illumination. Photochem Photobiol 1999; 70: 921-929.
5. de Bruijn HS, van der Veen N, Robinson DJ, Star WM. Improvement of systemic 5-aminolevulinic acid photodynamic therapy in vivo using light fractionation with a 75-minute interval. Cancer Res 1999; 59: 901-904.
6. Robinson DJ, de Bruijn HS, Star WM, Sterenborg HJCM. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 2003; 77: 319-323.
7. de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJCM, Robinson DJ. Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice; the influence of the dark interval. J Photochem Photobiol B Biol 2006; 85: 184-190.
8. de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A, Sterenborg HJCM, Robinson DJ. Evidence for a bystander role of neutrophils in systemic ALA-PDT using a two-fold illumination scheme. Photodermatol Photoimmunol Photomed 2006; 22: 238-246.
9. de Bruijn HS, de Haas ERM, Hebeda KM, van der Ploegvan den Heuvel A, Sterenborg HJCM, Neumann HAM, et al. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin. Photochem Photobiol Sci 2007; 12: 1325-1331.
10. Thissen MRTM, Robinson DJ, de Blois AW, de Bruijn HS, Dutrieux RP, Star WM, et al. PpIX fluorescence kinetics and increased skin damage after intracutaneous injection of 5-aminolevulinic acid and repeated illumination. J Invest Dermatol 2002; 118: 239-245
11. Moan J, Ma LW, Iani V, Juzeniene A. Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester. J Invest Dermatol 2005; 125: 1039-1044.
12. Juzenas P, Juzeniene A, Kaalhus O, Iani V, Moan J. Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem Photobiol Sci 2002; 1: 745-748.
13. Amelink A, van den Heuvel A, de Wolf WJ, Robinson DJ, Sterenborg HJCM. Monitoring PDT by means of superficial reflectance spectroscopy J Photochem Photobiol B Biol 2005; 79: 243-251.
14. Tope WD, Ross EV, Kollias N, Martin A, Gillies R, Anderson RR. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochem Photobiol 1998; 67: 249-255.
15. Heyerdahl H, Wang I, Liu DL, Berg R, Andersson-Engels S, Peng Q, et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett 1997; 112: 225-231.
16. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62: 906-913.
17. Leunig A, Mehlmann M, Betz C, Stepp H, Arbogast S, Grevers G, et al. Fluorescence staining of oral cancer using a topical application of 5-aminolevulinic acid: fluorescence microscopic studies. J Photochem Photobiol B 2001; 60: 44-49.
18. Fehr MK, Wyss P, Tromberg BJ, Krasieva T, DiSaia PJ, Lin F, et al. Selective photosensitizer localization in the human endometrium after intrauterine application of 5-aminolevulinic acid. Am J Obstet Gynecol 1996; 175: 1253-1259.
19. Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995; 287: 665-674.
20. Baum HP, Meurer I, Unteregger G. Ki67 antigen expression and growth pattern of basal cell carcinomas. Arch Dermatol Res 1993; 285: 291-295.
21. Horlock HM, Wilson GD, Daley FM, Richman PI, Sanders R. Cellular proliferation characteristics of basal cell carcinoma: relationship to clinical subtype and histopathology. Eur J Surg Oncol 1997; 23: 247-252.
22. Chang CH, Tsai RK, Chen GS, Yu HS, Chai CY. Expression of bcl-2, p53 and ki-67 in arsenic skin cancers. J Cutan Pathol 1998; 25: 457-462.
23. Tilli CMLJ, Stavast-Kooy AJW, Ramaekers FCS, Neumann HAM. Bax expression and growth behavior of basal cell carcinomas. J Cutan Pathol 2002; 29: 79-87.
24. Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA Sangueza OP. Immunohistochemical evaluation of basal cell carcinomas and trichoepithelioma using Bcl-2, Ki67 PCNA and P53. J Cutan Pathol 2000; 27: 169.
25. Tilli CMLJ, Van Steensel MAMA, Krekels GAM, Neumann HAM, Ramaekers FCS. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005; 152: 1108-1124.
26. Healy E, Angus B, Lawrence CM, Rees JL. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol 1995; 133: 737-741.
27. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004; 151: 656-662.
28. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-2308.
29. Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, van Hillegersberg R, Tilanus HW, et al. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998; 78: 679-682.
30. Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br J Cancer 1998; 78: 1278-1282.
31. Vereecken P, Da Costa CM, Steels E, De Lathouwer O, Heenen M, De Mey A. Fluorescence diagnosis of face-located basal cell carcinomas: a new dermatological procedure which may help the surgeon. Acta Chir Belg 2007; 107: 205-207.
32. Won Y, Hong SH, Yu HY, Kwon YH, Yun SJ, Lee SC, et al. Photodetection of basal cell carcinoma using methyl 5-aminolaevulinate-induced protoporphyrin IX based on fluorescence image analysis. Clin Exp Dermatol 2007; 32: 423-429.
33. Ericson MB, Sandberg C, Gudmundson F, Rosen A, Larkö O, Wennberg AM. Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma. J Photochem Photobiol B 2003; 69: 121-127.
34. Andersson-Engels S, Canti G, Cubeddu R, Eker C, af Klinteberg C, Pifferi A, et al. Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin. Lasers Surg Med 2000; 26: 76-82.
35. Stenquist B, Ericson MB, Strandeberg C, Mölne L, Rosen A, Larkö O, et al. Bispectral fluorescence imaging of aggressive basal cell carcinoma combined with histopathological mapping: a preliminary study indicating a possible adjunct to Mohs micrographic surgery. Br J Dermatol 2006; 154: 305-309.
36. de Bruijn HS, Kruijt B, van der Ploeg-van den Heuvel A, Sterenborg HJCM, Robinson DJ. Increase in protoporphyrin IX after 5-aminolevulinic acid based photodynamic therapy is due to local re-synthesis. Photochem Photobiol Sci 2007; 8: 857-864.